MedTrace Logo

Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTI

NCT01202279 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1179

Last updated 2020-12-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if treatment with Mucinex D lowers the use of antibiotics in the treatment of upper respiratory infection when compared to placebo

Conditions

  • Acute Upper Respiratory Track Infection

Interventions

DRUG

Guaifenesin

1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days

DEVICE

Placebo

Placebo bid for 7 days

Sponsors & Collaborators

  • Reckitt Benckiser Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-04-30
Completion
2010-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01202279 on ClinicalTrials.gov